Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Judd

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Journal of Medicinal Chemistry|January 24, 2012
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1Vince S C Yeh, David W A Beno, Sevan Brodjian, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Journal of Medicinal Chemistry|September 16, 2005
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Rajesh Iyengar, Andrew J Souers, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Journal of Medicinal Chemistry|January 24, 2012
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1Vince S C Yeh, David W A Beno, Sevan Brodjian, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Journal of Medicinal Chemistry|September 16, 2005
Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonistsPhilip R Kym, Rajesh Iyengar, Andrew J Souers, et al.
Science Advances|October 4, 2024
BCL-X<sub>L</sub>-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitorsAndrew S Judd, Bhupinder Bawa, Wayne R Buck, et al.
Pageof 9